Terms: = Ovarian cancer AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR AND Prognosis
12 results:
1. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous ovarian cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract] [Full Text] [Related]
2. foxo1 promotes ovarian cancer by increasing transcription and METTL14-mediated m
Tan L; Wang S; Huang S; Tie Y; Sai N; Mao Y; Zhao S; Hou Y; Dou H
Cancer Sci; 2024 Apr; 115(4):1224-1240. PubMed ID: 38403332
[TBL] [Abstract] [Full Text] [Related]
3. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
4. A novel autophagy-related gene signature associated with prognosis and immune microenvironment in ovarian cancer.
Yang J; Wang C; Zhang Y; Cheng S; Wu M; Gu S; Xu S; Wu Y; Wang Y
J Ovarian Res; 2023 Apr; 16(1):86. PubMed ID: 37120633
[TBL] [Abstract] [Full Text] [Related]
5. An integration analysis of mRNAs and miRNAs microarray data to identify key regulators for ovarian endometriosis based on competing endogenous RNAs.
Wang K; Sun Y; Wang Y; Liu L
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():468-475. PubMed ID: 32738676
[TBL] [Abstract] [Full Text] [Related]
6. foxo1 overexpression is correlated with poor prognosis in epithelial ovarian cancer.
Liu L; Yi J; Yuan J; Yao T; Lin Z; Ning Y; Zeng Z
Cancer Biomark; 2020; 28(1):1-8. PubMed ID: 32224523
[TBL] [Abstract] [Full Text] [Related]
7. Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/foxo1 pathway.
Ma L; Sun Y; Li D; Li H; Jin X; Ren D
Aging (Albany NY); 2020 Mar; 12(6):5336-5351. PubMed ID: 32202508
[TBL] [Abstract] [Full Text] [Related]
8. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer.
Gong G; Lin T; Yuan Y
J Ovarian Res; 2020 Mar; 13(1):30. PubMed ID: 32192517
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic implications of forkhead box protein O1 (foxo1) and paired box 3 (PAX3) in epithelial ovarian cancer.
Han GH; Chay DB; Nam S; Cho H; Chung JY; Kim JH
BMC Cancer; 2019 Dec; 19(1):1202. PubMed ID: 31823759
[TBL] [Abstract] [Full Text] [Related]
10. Integrated microarray meta-analysis identifies miRNA-27a as an oncogene in ovarian cancer by inhibiting foxo1.
Wang Z; Ji G; Wu Q; Feng S; Zhao Y; Cao Z; Tao C
Life Sci; 2018 Oct; 210():263-270. PubMed ID: 30138596
[TBL] [Abstract] [Full Text] [Related]
11. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Liu X; Chong Y; Liu H; Han Y; Niu M
J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
[TBL] [Abstract] [Full Text] [Related]
12. The foxo1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
Mozos A; Catasús L; D'Angelo E; Serrano E; Espinosa I; Ferrer I; Pons C; Prat J
Hum Pathol; 2014 May; 45(5):942-51. PubMed ID: 24746199
[TBL] [Abstract] [Full Text] [Related]
